Once scored as a po­ten­tial block­buster, No­var­tis’ sere­lax­in fiz­zles in crit­i­cal car­dio out­comes test

You can scratch sere­lax­in off No­var­tis’ list of po­ten­tial block­busters in the late-stage pipeline.

This morn­ing the phar­ma gi­ant said that its 4-year study of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA